C

China Resources Pharmaceutical Group Ltd
HKEX:3320

Watchlist Manager
China Resources Pharmaceutical Group Ltd
HKEX:3320
Watchlist
Price: 5.57 HKD 1.27% Market Closed
Market Cap: 35B HKD
Have any thoughts about
China Resources Pharmaceutical Group Ltd?
Write Note

China Resources Pharmaceutical Group Ltd
Other Long-Term Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

China Resources Pharmaceutical Group Ltd
Other Long-Term Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Long-Term Assets CAGR 3Y CAGR 5Y CAGR 10Y
C
China Resources Pharmaceutical Group Ltd
HKEX:3320
Other Long-Term Assets
HK$6.1B
CAGR 3-Years
18%
CAGR 5-Years
12%
CAGR 10-Years
N/A
G
Grand Pharmaceutical Group Ltd
HKEX:512
Other Long-Term Assets
HK$892m
CAGR 3-Years
38%
CAGR 5-Years
51%
CAGR 10-Years
11%
U
United Laboratories International Holdings Ltd
HKEX:3933
Other Long-Term Assets
ÂĄ87.8m
CAGR 3-Years
-9%
CAGR 5-Years
-22%
CAGR 10-Years
-13%
Sino Biopharmaceutical Ltd
HKEX:1177
Other Long-Term Assets
ÂĄ989.3m
CAGR 3-Years
-39%
CAGR 5-Years
-12%
CAGR 10-Years
6%
C
China Traditional Chinese Medicine Holdings Co Ltd
HKEX:570
Other Long-Term Assets
ÂĄ319.5m
CAGR 3-Years
19%
CAGR 5-Years
17%
CAGR 10-Years
-3%
H
HUTCHMED (China) Ltd
HKEX:13
Other Long-Term Assets
$37.3m
CAGR 3-Years
15%
CAGR 5-Years
21%
CAGR 10-Years
62%
No Stocks Found

China Resources Pharmaceutical Group Ltd
Glance View

Market Cap
35B HKD
Industry
Pharmaceuticals

In the vast and dynamic landscape of China's healthcare sector, China Resources Pharmaceutical Group Ltd. has emerged as a formidable player. Born from the rich heritage of its parent conglomerate, China Resources Holdings, the company weaves together a complex tapestry of pharmaceutical manufacturing, distribution, and retail operations. Its diversified operations ensure that it maintains a robust footprint across the entire pharmaceutical value chain. The company's manufacturing arm is a powerhouse, producing a vast array of products, including traditional Chinese medicine and modern pharmaceuticals, catering to the diverse needs of health consumers in China and beyond. Leveraging its extensive industry expertise and a deep understanding of the local market, China Resources Pharmaceutical crafts products that blend innovation with time-honored traditions, effectively meeting the growing demands for quality healthcare solutions. On the distribution and retail front, China Resources Pharmaceutical Group employs its extensive and well-integrated network to efficiently channel its products across the nation. The strategic positioning of its distribution centers enables it to serve hundreds of thousands of pharmacies, hospitals, and healthcare institutions, ensuring broad accessibility. Retail operations round out the company's comprehensive approach, with a wide-reaching chain of drugstores under its banner offering not only medicinal products but also healthcare services. This holistic business model not only diversifies revenue streams but also strengthens the company's ability to weather industry shifts, making it a resilient entity in the ever-evolving pharmaceutical and healthcare milieu. Through its multifaceted approach, China Resources Pharmaceutical Group Ltd. continues to play a crucial role in shaping the future of healthcare in China, navigating challenges and opportunities with the acuity expected of an industry leader.

Intrinsic Value
16.42 HKD
Undervaluation 66%
Intrinsic Value
Price
C

See Also

What is China Resources Pharmaceutical Group Ltd's Other Long-Term Assets?
Other Long-Term Assets
6.1B HKD

Based on the financial report for Jun 30, 2024, China Resources Pharmaceutical Group Ltd's Other Long-Term Assets amounts to 6.1B HKD.

What is China Resources Pharmaceutical Group Ltd's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 5Y
12%

Over the last year, the Other Long-Term Assets growth was 91%. The average annual Other Long-Term Assets growth rates for China Resources Pharmaceutical Group Ltd have been 18% over the past three years , 12% over the past five years .

Back to Top